You searched for "prevention"

2907 results found

Which patients are suitable for surgery in recurrent head and neck cancer?

Currently, radiotherapy and chemotherapy is the most common modality used in the management of primary head and neck squamous cell carcinomas (HNSCC). Unfortunately, around 50% of patients experience disease recurrence (rHNSCC). Surgery is therefore often used as a salvage treatment....

Bringing ear care and hearing services to the hardest to reach: the potential of primary healthcare workers

Can workers from the local community plug the workforce gap in providing ear and hearing care? Bringing ear and hearing care services closer to the community remains a key component of reducing the burden of ear and hearing conditions across...

Bringing ear care and hearing services to the hardest to reach: the potential of primary healthcare workers

Can workers from the local community plug the workforce gap in providing ear and hearing care? Bringing ear and hearing care services closer to the community remains a key component of reducing the burden of ear and hearing conditions across...

Dr Marion Pfaender Down

“Dr Marion P Downs, an innovator in the field of paediatric audiology and a tireless advocate for the early identification of hearing loss, passed away on November 13, 2014. During her exemplary career at the University of Colorado Health Sciences...

Polysolmnography and laryngomalacia severity

Laryngomalacia represents the single most common cause of stridor in infants. Most cases are self-resolving, but a proportion of children will require surgical intervention. This group aimed to analyse the efficacy of polysomnography in determining the severity of laryngomalacia in...

The EU Medical Device Regulation (MDR)

Back in May 2017, the EU Medical Device Regulation (MDR 2017/745) entered into force, replacing existing directives: Active Implantable Medical Devices (AIMD) In-vitro Diagnostic Directive (IVDD) Medical Device Directive (MDD) By 26 May 2020, the new regulation will have completed...

Alternative listening devices: reaching the places hearing aids don’t

The stigma surrounding hearing aids means that many people who would benefit from wearing them are put off from doing so. Alternative listening devices could provide the solution to this. David Maidment discusses these devices, their effectiveness and the impact...

Say what you don’t mean: cognitive difficulties in Parkinson’s can worsen intelligibility

Hypokinetic dysarthria, seen in 70–90% of people with Parkinson’s, causes reduced range of movement during speech production, reduced volume, rate, pitch and intelligibility. This study aimed to explore the role of higher cognitive function in speech production by asking 20...

5-cm incision for neck dissection and free flap reconstruction

Patients with oral cavity squamous cell carcinoma (SCC) will commonly require neck dissection as it is associated with a higher rate of overall and disease free survival. Free flap reconstruction of the defect following surgical resection is considered the gold...

Open hearing-aid fittings or closed

There is always a balance between different types of hearing aids and their advantages and disadvantages that influence choice of device and ultimately user preference. Personal choice also plays a role when deciding on behind the ear or in ear...

Preoperative planning of the surgical patient

This article covers the need to effectively optimise patient status preoperatively to help maximise postoperative outcomes. The article is well written and emphasises close liaison with anaesthetic colleagues particularly regarding airway assessment and nausea and vomiting. As is becoming common...

Amplifon’s $2 billion move into manufacturing: what it means for audiology

Our audiology editor Yovina Khiroya writes: Amplifon, the world’s largest hearing aid retailer, has announced a reported $2 billion acquisition of GN Hearing, the company behind ReSound, Beltone and Jabra Enhance. While headline-grabbing, the strategic implications are arguably more significant than the deal value itself.